NRx Pharmaceuticals, Inc.
NRXP
$2.75
$0.124.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -122.62% | 15.56% | -109.56% | 73.23% | 9.41% |
| Total Depreciation and Amortization | -- | -- | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 515.13% | 195.61% | 1,131.49% | -206.43% | 55.79% |
| Change in Net Operating Assets | -116.93% | -100.00% | -103.55% | -94.70% | 640.25% |
| Cash from Operations | -57.22% | 5.20% | 34.27% | 49.47% | 67.20% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 2,535.67% | -- | -- |
| Total Debt Repaid | -7,300.00% | 85.15% | -196.54% | 1.05% | 98.89% |
| Issuance of Common Stock | -100.00% | 27.65% | -- | -- | -43.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -55.75% | 1,820.25% | 269.80% | 236.84% | -49.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -555.61% | 225.31% | 95.29% | 95.85% | 137.67% |